Literature DB >> 20500549

A distinct nitric oxide and adenosine A1 receptor dependent hepatic artery vasodilatatory response in the CCl-cirrhotic liver.

Alexander Zipprich1, Wajahat Z Mehal, Cristina Ripoll, Roberto J Groszmann.   

Abstract

UNLABELLED: Increase of portal venous vascular resistance is counteracted by decrease of hepatic arterial vascular resistance (hepatic arterial buffer response). This process is mediated by adenosine in normal livers. In cirrhosis, hepatic arterial vascular resistance is decreased but the involvement of adenosine in this process is unknown. The aim of our study was to identify the signalling pathway responsible for the decreased hepatic arterial resistance in cirrhotic livers.
METHODS: Cirrhosis was induced by CCl(4). Using a bivascular liver perfusion dose-response curves to adenosine of the HA were performed in the presence and the absence of pan-adenosine blocker (8-SPT), A1 blocker (caffeine) or nitric oxide synthase-blocker (l-NMMA) after preconstriction with an alpha1-agonist (methoxamine). Western blot of the HA were used to measure the density of the A1 and A2a receptors.
RESULTS: Adenosine caused a dose dependent relaxation of the hepatic artery of both cirrhotic and control animals that were blocked in both groups by 8-SPT (P<0.02). The response to adenosine was greater in cirrhotic rats (P=0.016). Both l-NMMA (P=0.003) and caffeine reduced the response to adenosine in cirrhotic but not in control animals. Western blot analysis showed a higher density of A1 and a lower density of A2a receptor in cirrhotic animals (P<0.05).
CONCLUSION: The adenosine-induced vasodilatation of the HA is increased in cirrhotic rats suggesting a role for adenosine-NO in the decreased hepatic arterial vascular resistance found in cirrhosis. This significantly greater response in cirrhosis by the A1 receptor follows the same pathway that is seen in hypoxic conditions in extra-hepatic tissues.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20500549      PMCID: PMC3219754          DOI: 10.1111/j.1478-3231.2010.02278.x

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  25 in total

1.  Three-dimensional observations of the human hepatic artery (Arterial system in the liver).

Authors:  S Takasaki; H Hano
Journal:  J Hepatol       Date:  2001-03       Impact factor: 25.083

2.  Nitric oxide and vascular remodeling modulate hepatic arterial vascular resistance in the isolated perfused cirrhotic rat liver.

Authors:  Alexander Zipprich; Mauricio R Loureiro-Silva; Dhanpat Jain; Irita D'Silva; Roberto J Groszmann
Journal:  J Hepatol       Date:  2008-08-06       Impact factor: 25.083

3.  Role of endothelium in adenosine receptor-mediated vasorelaxation in hypertensive rats.

Authors:  M Fahim; T Hussain; S J Mustafa
Journal:  Fundam Clin Pharmacol       Date:  2001-10       Impact factor: 2.748

4.  Adenosine as putative regulator of hepatic arterial flow (the buffer response).

Authors:  W W Lautt; D J Legare; M S d'Almeida
Journal:  Am J Physiol       Date:  1985-03

5.  A simple and inexpensive membrane "lung" for small organ perfusion.

Authors:  R L Hamilton; M N Berry; M C Williams; E M Severinghaus
Journal:  J Lipid Res       Date:  1974-03       Impact factor: 5.922

Review 6.  Pharmacology of adenosine receptors in the vasculature.

Authors:  R Tabrizchi; S Bedi
Journal:  Pharmacol Ther       Date:  2001-08       Impact factor: 12.310

7.  Impact of intrinsic blood flow regulation in cirrhosis: maintenance of hepatic arterial buffer response.

Authors:  S Richter; I Mücke; M D Menger; B Vollmar
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2000-08       Impact factor: 4.052

8.  Hepatic arteriolo-portal venular shunting guarantees maintenance of nutritional microvascular supply in hepatic arterial buffer response of rat livers.

Authors:  S Richter; B Vollmar; I Mücke; S Post; M D Menger
Journal:  J Physiol       Date:  2001-02-15       Impact factor: 5.182

9.  Evolution of hypoxemia in patients with severe cirrhosis.

Authors:  Isabelle Colle; Philippe Langlet; Eric Barrière; Jörg Heller; Emmanuel Rassiat; Bertrand Condat; Alain Carayon; Dominique Valla; Richard Moreau; Didier Lebrec
Journal:  J Gastroenterol Hepatol       Date:  2002-10       Impact factor: 4.029

10.  Functional significance of hepatic arterial flow reserve in patients with cirrhosis.

Authors:  Alexander Zipprich; Norbert Steudel; Curd Behrmann; Frank Meiss; Ursula Sziegoleit; Wolfgang E Fleig; Gerhard Kleber
Journal:  Hepatology       Date:  2003-02       Impact factor: 17.425

View more
  8 in total

1.  Morphological and biomechanical remodelling of the hepatic artery in a swine model of portal hypertension.

Authors:  Xi-Ju He; Ming-Hua Yu; Wen-Chun Li; Han-Qin Wang; Jing Li; Xing-Chun Peng; Jie Tang; Na Feng; Tie-Zhu Huang
Journal:  Hepatol Int       Date:  2011-09-23       Impact factor: 6.047

Review 2.  Extrahepatic complications to cirrhosis and portal hypertension: haemodynamic and homeostatic aspects.

Authors:  Søren Møller; Jens H Henriksen; Flemming Bendtsen
Journal:  World J Gastroenterol       Date:  2014-11-14       Impact factor: 5.742

Review 3.  Evolution in the understanding of the pathophysiological basis of portal hypertension: How changes in paradigm are leading to successful new treatments.

Authors:  Jaume Bosch; Roberto J Groszmann; Vijay H Shah
Journal:  J Hepatol       Date:  2015-04       Impact factor: 25.083

Review 4.  Pathological roles of purinergic signaling in the liver.

Authors:  Byron P Vaughn; Simon C Robson; Geoffrey Burnstock
Journal:  J Hepatol       Date:  2012-06-16       Impact factor: 25.083

Review 5.  Purinergic signalling in the liver in health and disease.

Authors:  Geoffrey Burnstock; Byron Vaughn; Simon C Robson
Journal:  Purinergic Signal       Date:  2013-11-24       Impact factor: 3.765

6.  Hepatic arterial vasodilation is independent of portal hypertension in early stages of cirrhosis.

Authors:  Miriam Moeller; Antje Thonig; Sabine Pohl; Cristina Ripoll; Alexander Zipprich
Journal:  PLoS One       Date:  2015-03-20       Impact factor: 3.240

Review 7.  Congestive Hepatopathy.

Authors:  José Ignacio Fortea; Ángela Puente; Antonio Cuadrado; Patricia Huelin; Raúl Pellón; Francisco José González Sánchez; Marta Mayorga; María Luisa Cagigal; Inés García Carrera; Marina Cobreros; Javier Crespo; Emilio Fábrega
Journal:  Int J Mol Sci       Date:  2020-12-10       Impact factor: 5.923

Review 8.  Purinergic signaling in liver disease.

Authors:  Byron P Vaughn; Simon C Robson; Maria Serena Longhi
Journal:  Dig Dis       Date:  2014-07-14       Impact factor: 2.404

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.